Balaji Amines Ltd
Incorporate in 1989, Balaji Amines Ltd is engaged in manufacturing of specialty chemicals, aliphatic amines, and derivatives, along with ownership of a five-star hotel in Solapur, Maharashtra.[1]
- Market Cap ₹ 7,412 Cr.
- Current Price ₹ 2,288
- High / Low ₹ 2,630 / 905
- Stock P/E 37.5
- Book Value ₹ 551
- Dividend Yield 0.48 %
- ROCE 13.3 %
- ROE 9.61 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 21.7%
Cons
- Stock is trading at 4.15 times its book value
- The company has delivered a poor sales growth of 0.95% over past five years.
- Company has a low return on equity of 10.3% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 602 | 632 | 665 | 858 | 947 | 918 | 1,227 | 1,914 | 1,720 | 1,330 | 1,266 | 1,287 | 1,395 | |
| 500 | 503 | 513 | 676 | 753 | 738 | 901 | 1,473 | 1,391 | 1,083 | 1,040 | 1,040 | 1,101 | |
| Operating Profit | 102 | 129 | 151 | 182 | 193 | 180 | 327 | 441 | 330 | 247 | 226 | 247 | 294 |
| OPM % | 17% | 20% | 23% | 21% | 20% | 20% | 27% | 23% | 19% | 19% | 18% | 19% | 21% |
| 3 | 2 | 9 | 12 | 5 | 10 | 12 | 18 | 10 | 21 | 23 | 28 | 27 | |
| Interest | 31 | 20 | 12 | 9 | 13 | 12 | 5 | 7 | 3 | 2 | 2 | 2 | 2 |
| Depreciation | 19 | 18 | 18 | 19 | 20 | 24 | 23 | 29 | 31 | 34 | 38 | 46 | 46 |
| Profit before tax | 56 | 93 | 130 | 166 | 166 | 154 | 310 | 423 | 305 | 232 | 209 | 227 | 273 |
| Tax % | 35% | 34% | 34% | 32% | 29% | 26% | 25% | 27% | 25% | 26% | 25% | 27% | |
| 36 | 61 | 86 | 113 | 118 | 114 | 232 | 308 | 228 | 171 | 156 | 166 | 198 | |
| EPS in Rs | 11.22 | 18.91 | 26.41 | 34.93 | 36.44 | 35.11 | 71.51 | 95.04 | 70.23 | 52.87 | 48.21 | 51.09 | 61.08 |
| Dividend Payout % | 11% | 11% | 8% | 7% | 8% | 9% | 6% | 6% | 14% | 21% | 23% | 22% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 1% |
| 3 Years: | -9% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -6% |
| 3 Years: | -10% |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | -13% |
| 3 Years: | 1% |
| 1 Year: | 64% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 231 | 285 | 371 | 461 | 569 | 661 | 891 | 1,186 | 1,394 | 1,528 | 1,649 | 1,778 |
| 236 | 159 | 103 | 115 | 95 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 129 | 156 | 175 | 237 | 327 | 334 | 394 | 292 | 151 | 202 | 195 | 238 | |
| Total Liabilities | 603 | 607 | 655 | 819 | 997 | 1,104 | 1,292 | 1,484 | 1,551 | 1,736 | 1,850 | 2,024 |
| 321 | 322 | 309 | 316 | 318 | 363 | 344 | 495 | 604 | 724 | 833 | 883 | |
| CWIP | 3 | 16 | 25 | 66 | 63 | 46 | 173 | 141 | 74 | 143 | 154 | 203 |
| Investments | 30 | 30 | 30 | 66 | 66 | 114 | 66 | 66 | 128 | 66 | 66 | 66 |
| 249 | 238 | 292 | 371 | 550 | 581 | 708 | 782 | 745 | 803 | 797 | 872 | |
| Total Assets | 603 | 607 | 655 | 819 | 997 | 1,104 | 1,292 | 1,484 | 1,551 | 1,736 | 1,850 | 2,024 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | 84 | 72 | 126 | 89 | 148 | 94 | 176 | 187 | 217 | 224 | 200 | |
| -14 | -30 | -23 | -93 | -47 | -130 | -87 | -142 | -155 | -190 | -179 | -129 | |
| -49 | -52 | -54 | -29 | -29 | -31 | 3 | -20 | -22 | -35 | -38 | -36 | |
| Net Cash Flow | -3 | 2 | -5 | 4 | 13 | -13 | 10 | 14 | 10 | -8 | 8 | 35 |
| Free Cash Flow | 52 | 51 | 59 | 58 | 70 | 95 | -37 | 28 | 111 | -5 | 67 | 56 |
| CFO/OP | 68% | 75% | 65% | 93% | 72% | 111% | 40% | 64% | 78% | 107% | 117% | 95% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70 | 69 | 67 | 73 | 64 | 76 | 81 | 83 | 55 | 72 | 71 | 84 |
| Inventory Days | 93 | 62 | 88 | 70 | 100 | 66 | 56 | 69 | 97 | 127 | 129 | 111 |
| Days Payable | 46 | 57 | 55 | 56 | 58 | 40 | 43 | 57 | 13 | 35 | 34 | 26 |
| Cash Conversion Cycle | 117 | 74 | 100 | 87 | 106 | 102 | 94 | 95 | 139 | 164 | 166 | 169 |
| Working Capital Days | 2 | 6 | 31 | 29 | 46 | 46 | 80 | 80 | 98 | 118 | 117 | 112 |
| ROCE % | 19% | 24% | 30% | 33% | 29% | 23% | 38% | 41% | 24% | 16% | 13% | 13% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Export Revenue Share % |
|
||||||
| Installed Capacity MTPA |
|||||||
| Hotel Occupancy Rate % |
|||||||
| Hotel RevPAR Rs |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Regulation 74(5) certificate filed for quarter ended 30 September 2026.
-
Disclosure Under Regulation 30(2) Read With Regulation 30(6) Of, And Sub-Para 20 Of Para A Of Part A Of Schedule III Of The SEBI (LODR) Regulations, 2015
- SEBI issued warning cum advisory letter for non-submission of Regulation 30 disclosures.
-
Disclosure Under Regulation 30(2) Read With Regulation 30(6) Of, And Sub-Para 20 Of Para A Of Part A Of Schedule III Of The SEBI (LODR) Regulations, 2015
- FDA Pune issued a warning letter over propylene glycol resale; no penalty or operational impact.
-
Disclosure Under Regulation 30(2) Read With Regulation 30(6) Of, And Sub-Para 20 Of Para A Of Part A Of Schedule III Of The SEBI (LODR) Regulations, 2015
- DGFT put license 3111001781 in Denied Entity List for export obligation violation.
-
Announcement under Regulation 30 (LODR)-Change in Management
- Mr. Rajendrakumar Tapadiya’s tenure ended as Independent Director of Balaji Speciality Chemicals Limited on 28 September 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Jul 2026PPT
-
May 2026Transcript PPT REC
-
Jan 2026PPT
-
Nov 2025Transcript PPT
-
Aug 2025PPT
-
Jun 2025Transcript PPT
-
Feb 2025PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024PPT
-
May 2024Transcript
-
May 2024Transcript PPT
-
Feb 2024PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023PPT
-
Oct 2022PPT
-
Aug 2022PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020PPT
-
Dec 2019Transcript PPT
-
Nov 2019PPT
-
Aug 2019Transcript PPT
-
Jul 2019PPT
-
May 2019Transcript
-
Aug 2018Transcript
-
May 2018Transcript
-
Feb 2018Transcript
-
Feb 2017Transcript
-
Feb 2017Transcript
Market Leadership[1]
The Company is the largest manufacturer of aliphatic amines and methylamines in India, the only domestic company to develop indigenous amines manufacturing technology, and the sole Indian producer of several specialty chemicals